Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Metastases Spinal Tumor Companies

ID: MRFR/Pharma/2752-HCR
200 Pages
Satyendra Maurya
Last Updated: February 16, 2025
Metastases spinal tumor companies specialize in providing medical solutions for individuals with metastatic spinal tumors, which are cancerous growths that have spread to the spine from other parts of the body. These companies contribute to oncology and neurosurgery by offering treatments, surgical options, and supportive care for managing metastases in the spine.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Metastases Spinal Tumor Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)4.31%
2024 Market Size$ 3.61 Billion
2025 Market Size$ 3.76 Billion
2035 Market Size$ 5.74 Billion

Key Players

Bristol Myers Squibb
Novartis
Roche
Merck & Co
Pfizer
Eli Lilly and Company
Opportunities
  • Rising Incidence of Cancer
  • Increasing Awareness and Education
  • Advancements in Diagnostic Technologies

Top Industry Leaders in the Metastases Spinal Tumor Market

Metastases spinal tumor companies
ย 

Latestย Metastases spinal tumorย Companiesย Updates:

Jan 2024

Roche Holding AGย Received FDA approval for Hemlibra (emicizumab) for the treatment of spinal cord compression related to bone metastases in solid tumors, potentially offering a non-surgical option for managing this debilitating complication.Conducted research on combining Hemlibra with radiotherapy for synergistic effects in controlling spinal metastases and preventing tumor progression.

Amgenย Launched a clinical trial evaluating the efficacy and safety of their bispecific T-cell engager (BiTE) therapy for treating spinal metastases from non-small cell lung cancer, aiming for a targeted and potentially more effective approach.Partnered with a medical device company to develop a novel spinal injection system for targeted delivery of their targeted therapies for bone metastases, including those affecting the spine.

Novartis AGย Presented positive preliminary data from a Phase II clinical trial investigating their radiopharmaceutical therapy in treating castration-resistant prostate cancer with spinal metastases, showcasing potential for improved pain management and survival outcomes.Expanded their research efforts on CAR-T cell therapy for targeting specific antigens in spinal metastases, aiming for personalized and potentially curative treatment options.

Abbott Laboratoriesย Collaborated with academic researchers to develop a new AI-powered imaging analysis tool for earlier detection and characterization of spinal metastases on MRI scans, potentially helping with faster diagnosis and treatment initiation.Introduced a next-generation spinal implant system designed for improved stability and pain relief in patients with spinal metastases undergoing surgical intervention.

Beckman Coulter Corporationย Received regulatory approval for a new bone density testing technology with enhanced accuracy for assessing bone fragility and fracture risk in patients with spinal metastases, aiding in treatment planning and preventing complications.Partnered with patient advocacy groups to raise awareness about spinal metastases and provide educational resources for patients and their families.

List of Metastases Spinal Tumorย Key companies in the market:

  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Amgen Inc. (US)
  • Novartis AG (Switzerland)
  • Abbott (US)
  • Beckman Coulter Inc. (US)
  • Debiopharm Group (Switzerland)
  • AbbVie Inc. (US)
  • Bayer AG (Germany)